Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 4/2018

01.08.2018 | Review Article

Emerging Therapies for Acne Vulgaris

verfasst von: Megha K. Trivedi, Suzana S. Bosanac, Raja K. Sivamani, Larissa N. Larsen

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

As we gain a greater understanding of acne pathogenesis, both new agents as well as new uses for established drugs are being considered for the treatment of acne vulgaris. Multiple clinical trials assessing new formulations or combinations of established acne treatments have been conducted, and novel uses of antimicrobials such as modified diallyl disulfide oxide and nitric oxide are being assessed in clinical trials. There are also a multitude of new therapies currently being studied that target the inflammatory cascade of acne pathogenesis, including sebosuppressive and anti-inflammatory phytochemicals, and  small molecule inhibitors targeting sebaceous glands and enzymes, among others. Laser and light therapy is also being modified for the treatment of acne through combination methods with metal nanoshells and vacuum assistance. Probiotics have gained popularity in medicine as greater knowledge of the microbiome and its effects on multiple organ systems is being elucidated. Studies describing the positive effects of certain ammonia-oxidizing bacterial strains in the regulation of the skin’s inflammatory response are ongoing. Therapies for acne are constantly evolving and current gold-standard acne therapy may be supplemented with novel treatment modalities in the near future.
Literatur
1.
Perkins AC, Maglione J, Hillebrand GG, Miyamoto K, Kimball AB. Acne vulgaris in women: prevalence across the life span. J Womens Health. 2012;21(2):223–30.CrossRef
2.
Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–34.CrossRefPubMed
3.
Silverberg JI, Silverberg NB. Epidemiology and extracutaneous comorbidities of severe acne in adolescence: a US population-based study. Br J Dermatol. 2014;170(5):1136–42.CrossRefPubMed
4.
Cresce ND, Davis SA, Huang WW, Feldman SR. The quality of life impact of acne and rosacea compared to other major medical conditions. J Drugs Dermatol. 2014;13(6):692–7.PubMed
5.
Anderson KL, Dothard EH, Huang KE, Feldman SR. Frequency of primary nonadherence to acne treatment. JAMA Dermatol. 2015;151(6):623–6.CrossRefPubMed
6.
Yentzer BA, Ade RA, Fountain JM, Clark AR, Taylor SL, Fleischer AB Jr, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010;86(2):103–8.PubMed
7.
Fan Y, Hao F, Wang W, Lu Y, He L, Wang G, et al. Multicenter cross-sectional observational study of antibiotic resistance and the genotypes of Propionibacterium acnes isolated from Chinese patients with acne vulgaris. J Dermatol. 2016;43(4):406–13.CrossRefPubMed
8.
Mendoza N, Hernandez PO, Tyring SK, Haitz KA, Motta A. Antimicrobial susceptibility of Propionibacterium acnes isolates from acne patients in Colombia. Int J Dermatol. 2013;52(6):688–92.CrossRefPubMed
9.
Schafer F, Fich F, Lam M, Gárate C, Wozniak A, Garcia P. Antimicrobial susceptibility and genetic characteristics of Propionibacterium acnes isolated from patients with acne. Int J Dermatol. 2013;52(4):418–25.CrossRefPubMed
10.
Narayanan V, Motlekar S, Kadhe G, Bhagat S. Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies. Dermatol Ther. 2014;4(2):233–48.CrossRef
11.
Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J Am Acad Dermatol. 1991;25(4):674–81.CrossRefPubMed
12.
Tunca M, Akar A, Ozmen I, Erbil H. Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne. Int J Dermatol. 2010;49(12):1440–4.CrossRefPubMed
13.
Shah BJ, Sumathy TK, Dhurat RS, Torsekar RG, Viswanath V, Mukhi JI, et al. Efficacy and tolerability of topical fixed combination of nadifloxacin 1% and adapalene 0.1% in the treatment of mild to moderate acne vulgaris in indian patients: a multicenter, open-labelled, prospective study. Indian J Dermatol. 2014;59(4):385.CrossRefPubMedPubMedCentral
14.
Sato T, Shirane T, Noguchi N, Sasatsu M, Ito A. Novel anti-acne actions of nadifloxacin and clindamycin that inhibit the production of sebum, prostaglandin E2 and promatrix metalloproteinase-2 in hamster sebocytes. J Dermatol. 2012;39(9):774–80.CrossRefPubMed
15.
Emingil G, Atilla G, Sorsa T, Luoto H, Kirilmaz L, Baylas H. The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis. J Periodontol. 2004;75(1):106–15.CrossRefPubMed
16.
Zhang C, Gong W, Liu H, Guo Z, Ge S. Inhibition of matrix metalloproteinase-9 with low-dose doxycycline reduces acute lung injury induced by cardiopulmonary bypass. Int J Clin Exp Med. 2014;7(12):4975.PubMedPubMedCentral
17.
Esterly NB, Koransky JS, Furey NL, Trevisan M. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol. 1984;120(10):1308–13.CrossRefPubMed
18.
Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol. 1978;70(1):51–5.CrossRefPubMed
19.
Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139(4):459–64.CrossRefPubMed
20.
21.
Shemer A, Shiri J, Mashiah J, Farhi R, Gupta AK. Topical minocycline foam for moderate to severe acne vulgaris: phase 2 randomized double-blind, vehicle-controlled study results. J Am Acad Dermatol. 2016;74(6):1251–2.CrossRefPubMed
22.
23.
24.
Ortega-Peña S, Hidalgo-González C, Robson MC, Krötzsch E. In vitro microbicidal, anti-biofilm and cytotoxic effects of different commercial antiseptics. Int Wound J. 2017;14(3):470–9.CrossRefPubMed
25.
26.
Knüppel L, Ishikawa Y, Aichler M, Heinzelmann K, Hatz R, Behr J, et al. A novel antifibrotic mechanism of nintedanib and pirfenidone: inhibition of collagen fibril assembly. Am J Respir Cell Mol Biol. 2017;57(1):77–90.CrossRefPubMed
27.
Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol. 2004;75(1):39–48.CrossRefPubMed
28.
Braff MH, Zaiou M, Fierer J, Nizet V, Gallo RL. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect Immun. 2005;73(10):6771–81.CrossRefPubMedPubMedCentral
29.
Sader HS, Fedler KA, Rennie RP, Stevens S, Jones RN. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother. 2004;48(8):3112–8.CrossRefPubMedPubMedCentral
30.
Rubinchik E, Dugourd D, Algara T, Pasetka C, Friedland HD. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents. 2009;34(5):457–61.CrossRefPubMed
31.
Cutanea Life Sciences, Inc. A Phase 2, randomized, double-blind, vehicle-controlled, parallel group multicenter study to evaluate the safety and efficacy of CLS001 topical gel versus vehicle applied once daily for 12 weeks to female subjects with moderate to severe acne vulgaris [cited 10 Jul 2017]. https://​clinicaltrials.​gov/​ct2/​show/​NCT02571998.
32.
Faccone D, Veliz O, Corso A, Noguera M, Martínez M, Payes C, et al. Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates. Eur J Med Chem. 2014;71:31–5.CrossRefPubMed
33.
Green SJ, Mellouk S, Hoffman SL, Meltzer MS, Nacy CA. Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from l-arginine by macrophages and hepatocytes. Immunol Lett. 1990;25(1–3):15–9.CrossRefPubMed
34.
Green SJ, Nacy CA, Schreiber RD, Granger DL, Crawford RM, Meltzer MS, et al. Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from l-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun. 1993;61(2):689–98.PubMedPubMedCentral
35.
Qin M, Landriscina A, Rosen JM, Wei G, Kao S, Olcott W, et al. Nitric oxide-releasing nanoparticles prevent propionibacterium acnes–induced inflammation by both clearing the organism and inhibiting microbial stimulation of the innate immune response. J Invest Dermatol. 2015;135(11):2723–31.CrossRefPubMedPubMedCentral
36.
Baldwin H, Blanco D, McKeever C, Paz N, Vasquez YN, Quiring J, et al. Results of a phase 2 efficacy and safety study with SB204, an investigational topical nitric oxide-releasing drug for the treatment of acne vulgaris. J Clin Aesthet Dermatol. 2016;9(8):12.PubMedPubMedCentral
37.
Chen S, Ostrowski J, Whiting G, Roalsvig T, Hammer L, Currier SJ, et al. Retinoic acid receptor gamma mediates topical retinoid efficacy and irritation in animal models. J Invest Dermatol. 1995;104(5):779–83.CrossRefPubMed
38.
Jerry T, Ulrike B-P. A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50 μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris [cited 10 Jul 2017]. https://​clinicaltrials.​gov/​ct2/​show/​NCT02566369. Accessed 17 Jun 2017.
39.
Celasco G, Moro L, Bozzella R, Ferraboschi P, Bartorelli L, Quattrocchi C, et al. Biological profile of cortexolone 17a-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881–6.PubMed
40.
Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol. 2008;58(1):60–2.CrossRefPubMed
41.
Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;7:CD004425.
42.
Trifu V, Tiplica G-S, Naumescu E, Zalupca L, Moro L, Celasco G. Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0· 05% cream. Br J Dermatol. 2011;165(1):177–83.CrossRefPubMed
43.
Kohler C, Tschumi K, Bodmer C, Schneiter M, Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol. 2007;23(3):142–5.CrossRefPubMed
44.
Kumar R, Singh B, Bakshi G, Katare OP. Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation. Pharm Dev Technol. 2007;12(6):591–601.CrossRefPubMed
45.
Boen M, Brownell J, Patel P, Tsoukas MM. the role of photodynamic therapy in acne: an evidence-based review. Am J Clin Dermatol. 2017;18(3):311–21.CrossRefPubMed
46.
Kwon HH, Moon KR, Park SY, Yoon JY, Suh DH, Lee JB. Daylight photodynamic therapy with 1.5% 3-butenyl 5-aminolevulinate gel as a convenient, effective and safe therapy in acne treatment: a double-blind randomized controlled trial. J Dermatol. 2016;43(5):515–21.CrossRefPubMed
47.
Alexiades M. Laser and light-based treatments of acne and acne scarring. Clin Dermatol. 2017;35(2):183–9.CrossRefPubMed
48.
Momen S, Al-Niaimi F. Acne vulgaris and light-based therapies. J Cosmet Laser Ther. 2015;17(3):122–8.CrossRefPubMed
49.
Cohen BE, Brauer JA, Geronemus RG. Acne scarring: a review of available therapeutic lasers. Lasers Surg Med. 2016;48(2):95–115.CrossRefPubMed
50.
Qureshi S, Lin JY. Utilizing non-ablative fractional photothermolysis prior to ALA-photodynamic therapy in the treatment of acne vulgaris: a case series. Lasers Med Sci. 2017;32(3):729–32.CrossRefPubMed
51.
52.
Mercola JM, Kirsch DL. The basis for microcurrent electrical therapy in conventional medical practice. J Adv Med. 1995;8(2):107–20.
53.
54.
Paithankar DY, Sakamoto FH, Farinelli WA, Kositratna G, Blomgren RD, Meyer TJ, et al. Acne treatment based on selective photothermolysis of sebaceous follicles with topically delivered light-absorbing gold microparticles. J Invest Dermatol. 2015;135(7):1727–34.CrossRefPubMedPubMedCentral
55.
Hirsch LR, Gobin AM, Lowery AR, Tam F, Drezek RA, Halas NJ, et al. Metal nanoshells. Ann Biomed Eng. 2006;34(1):15–22.CrossRefPubMed
56.
Politi Y, Levi A, Enk CD, Lapidoth M. Integrated cooling-vacuum-assisted 1540-nm erbium: glass laser is effective in treating mild-to-moderate acne vulgaris. Lasers Med Sci. 2015;30(9):2389–93.CrossRefPubMed
57.
58.
59.
Karimipour DJ, Karimipour G, Orringer JS. Microdermabrasion: an evidence-based review. Plast Reconstr Surg. 2010;125(1):372–7.CrossRefPubMed
60.
Lloyd JR. The use of microdermabrasion for acne: a pilot study. Dermatol Surg. 2001;27(4):329–31.PubMed
61.
62.
Fisk WA, Lev-Tov HA, Sivamani RK. Botanical and phytochemical therapy of acne: a systematic review. Phytother Res. 2014;28(8):1137–52.CrossRefPubMed
63.
Yoon JY, Kwon HH, Min SU, Thiboutot DM, Suh DH. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. J Invest Dermatol. 2013;133(2):429–40.CrossRefPubMed
64.
Kim SY, Hyun MY, Go KC, Zouboulis CC, Kim BJ. Resveratrol exerts growth inhibitory effects on human SZ95 sebocytes through the inactivation of the PI3-K/Akt pathway. Int J Mol Med. 2015;35(4):1042–50.CrossRefPubMed
65.
Fabbrocini G, Staibano S, De Rosa G, Battimiello V, Fardella N, Ilardi G, et al. Resveratrol-containing gel for the treatment of acne vulgaris. Am J Clin Dermatol. 2011;12(2):133–41.CrossRefPubMed
66.
Eisinger M, Li W-H, Anthonavage M, Pappas A, Zhang L, Rossetti D, et al. A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids. J Dermatol Sci. 2011;63(1):23–32.CrossRefPubMed
67.
Zhang L, Li W-H, Anthonavage M, Eisinger M. Melanocortin-5 receptor: a marker of human sebocyte differentiation. Peptides. 2006;27(2):413–20.CrossRefPubMed
68.
Zhang L, Anthonavage M, Huang Q. LI W-H, Eisinger M. Proopiomelanocortin peptides and sebogenesis. Ann N Y Acad Sci. 2003;994(1):154–61.CrossRefPubMed
69.
Zhang L, Li W-H, Anthonavage M, Pappas A, Rossetti D, Cavender D, et al. Melanocortin-5 receptor and sebogenesis. Eur J Pharmacol. 2011;660(1):202–6.CrossRefPubMed
70.
71.
72.
Rosenkranz AA, Slastnikova TA, Durymanov MO, Sobolev AS. Malignant melanoma and melanocortin 1 receptor. Biochem (Mosc). 2013;78(11):1228–37.CrossRef
73.
Steck MB. The role of melanocortin 1 receptor in cutaneous malignant melanoma: along the mitogen-activated protein kinase pathway. Biol Res Nurs. 2014;16(4):421–8.CrossRefPubMed
74.
Selway JL, Kurczab T, Kealey T, Langlands K. Toll-like receptor 2 activation and comedogenesis: implications for the pathogenesis of acne. BMC Dermatol. 2013;13(1):10.CrossRefPubMedPubMedCentral
75.
Li ZJ, Choi DK, Sohn KC, Seo MS, Lee HE, Lee Y, et al. Propionibacterium acnes activates the NLRP3 inflammasome in human sebocytes. J Invest Dermatol. 2014;134(11):2747–56.CrossRefPubMed
76.
77.
78.
Kelhälä H-L, Palatsi R, Fyhrquist N, Lehtimäki S, Väyrynen JP, Kallioinen M, et al. IL-17/Th17 pathway is activated in acne lesions. PLoS One. 2014;9(8):e105238.CrossRefPubMedPubMedCentral
79.
Agak GW, Qin M, Nobe J, Kim M-H, Krutzik SR, Tristan GR, et al. Propionibacterium acnes induces an IL-17 response in acne vulgaris that is regulated by vitamin A and vitamin D. J Invest Dermatol. 2014;134(2):366–73.CrossRefPubMed
80.
Novartis Pharmaceuticals. A Randomized, Subject and Investigator Blinded, Placebo-controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne [cited 10 Jul 2017]. https://​clinicaltrials.​gov/​ct2/​show/​NCT02998671. Accessed 17 Jun 2017.
81.
Zouboulis CC, Seltmann H, Alestas T. Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis. Exp Dermatol. 2010;19(2):148–50.CrossRefPubMed
82.
83.
Alestas T, Ganceviciene R, Fimmel S, Müller-Decker K, Zouboulis CC. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med. 2006;84(1):75–87.CrossRefPubMed
84.
Aslam I, Fleischer A, Feldman S. Emerging drugs for the treatment of acne. Expert Opin Emerg Drugs. 2015;20(1):91–101.CrossRefPubMed
85.
Uto Y. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors. Chem Phys Lipids. 2016;197:3–12.CrossRefPubMed
86.
Meingassner JG, Aschauer H, Winiski AP, Dales N, Yowe D, Winther MD, et al. Pharmacological inhibition of stearoyl CoA desaturase in the skin induces atrophy of the sebaceous glands. J Invest Dermatol. 2013;133(8):2091.CrossRefPubMed
87.
Y Paul Goldberg, Xenon Pharmaceuticals Inc. A Phase 1 and 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, and Exposure of up to 12 Weeks of XPF-005 Treatment in Healthy Volunteers and Subjects With Acne Vulgaris [cited 10 Jul 2017]. https://​clinicaltrials.​gov/​ct2/​show/​NCT02656043. Accessed 17 Jun 2017.
88.
Bissonnette R, Poulin Y, Drew J, Hofland H, Tan J. Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: a phase IIa, multicenter, randomized, vehicle-controlled study. J Am Acad Dermatol. 2017;76(1):33–9.CrossRefPubMed
89.
Hunt DW, Winters GC, Brownsey RW, Kulpa JE, Gilliland KL, Thiboutot DM, et al. Inhibition of sebum production with the acetyl coenzyme a carboxylase inhibitor olumacostat glasaretil. J Invest Dermatol. 2017;137(7):1415–23.CrossRefPubMed
90.
91.
Jalian HR, Tam J, Vuong LN, Fisher J, Garibyan L, Mihm MC, et al. Selective cryolysis of sebaceous glands. J Invest Dermatol. 2015;135(9):2173–80.CrossRef
92.
Li ZJ, Park SB, Sohn KC, Lee Y, Seo YJ, Kim CD, et al. Regulation of lipid production by acetylcholine signalling in human sebaceous glands. J Dermatol Sci. 2013;72(2):116–22.CrossRefPubMed
93.
94.
95.
Fuchs-Tarlovsky V, Marquez-Barba MF, Sriram K. Probiotics in dermatologic practice. Nutrition. 2016;32(3):289–95.CrossRefPubMed
96.
Kramer S. Nitrosomonas eutropha: a Study of the effects of nitrosomonas on pathogenic bacterium and the effects of current hygiene habits on the colonization of nitrosomonas within our normal flora. JCCC Honors J. 2016;7(1):3.
97.
Noah Craft, Science 37. A Randomized, Double Blinded, Phase IIb/III, Decentralized study of B244 delivered as a topical spray to determine safety and efficacy in participants with mild to moderate Acne Vulgaris [cited 10 Jul 2017]. https://​clinicaltrials.​gov/​ct2/​show/​NCT02832063. Accessed 17 Jun 2017.
Metadaten
Titel
Emerging Therapies for Acne Vulgaris
verfasst von
Megha K. Trivedi
Suzana S. Bosanac
Raja K. Sivamani
Larissa N. Larsen
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 4/2018
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-018-0345-x

Weitere Artikel der Ausgabe 4/2018

American Journal of Clinical Dermatology 4/2018 Zur Ausgabe

Review Article

Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review

Systematic Review

Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis

Review Article

Therapeutics for Adult Nail Psoriasis and Nail Lichen Planus: A Guide for Clinicians

Review Article

Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges

Systematic Review

Acne Scarring Management: Systematic Review and Evaluation of the Evidence

Review Article

Skin Cancer Following Solid Organ Transplantation: A Review of Risk Factors and Models of Care

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise